+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07750470

Evaluating Accuracy of 18F-FDG PETCT Imaging for Staging and Chemotherapy Response in Muscle-invasive Bladder Cancer

Led by University Hospital of Ferrara · Updated on 2026-08-06

60

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the accuracy of a special imaging method called 18FFDG PETCT in patients newly diagnosed with high-grade muscle-invasive bladder cancer MIBC. This study aims to compare this imaging technique with the standard contrast-enhanced CT ceCT for initial cancer staging and to see how well it can predict the response to chemotherapy before surgery. The study is non-profit and will involve 60 participants at a single center. Participants will undergo baseline imaging with both 18FFDG PETCT and ceCT scans of the chest, abdomen, and pelvis. After two cycles of planned neoadjuvant chemotherapy each cycle lasting 21 days, the imaging procedures will be repeated to evaluate changes. The PETCT scans include a dynamic pelvic phase to improve accuracy by reducing interference from urinary tracer. During the study, participants will be monitored through these imaging assessments to measure how accurately the scans detect cancer spread and predict treatment response. Researchers will also explore additional imaging techniques and use advanced modeling to improve predictions. The main outcomes focus on baseline staging accuracy and predictive ability after chemotherapy, with the study expected to complete in December 2026.

CONDITIONS

Brief Title

Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here